Tower Research Capital (TRC)’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-3,276
| Closed | -$6.39K | – | 6356 |
|
|
2023
Q4 | $6.39K | Buy |
3,276
+1,085
| +50% | +$2.18K | ﹤0.01% | 4747 |
|
|
2023
Q3 | $5.26K | Sell |
2,191
-521
| -19% | -$1.28K | ﹤0.01% | 4744 |
|
|
2023
Q2 | $8K | Buy |
+2,712
| New | +$14.4K | ﹤0.01% | 4489 |
|
|
2022
Q2 | – | Sell |
-10
| Closed | -$4K | – | 6842 |
|
|
2022
Q1 | $4K | Buy |
10
+1
| +11% | +$638 | ﹤0.01% | 5307 |
|
|
2021
Q4 | $9K | Buy |
+9
| New | +$12.7K | ﹤0.01% | 4753 |
|
|
2021
Q3 | – | Sell |
-13
| Closed | -$34K | – | 6388 |
|
|
2021
Q2 | $34K | Buy |
13
+9
| +225% | +$29.7K | ﹤0.01% | 3372 |
|
|
2021
Q1 | $15K | Buy |
4
+1
| +33% | +$5.41K | ﹤0.01% | 4134 |
|
|
2020
Q4 | $18K | Sell |
3
-30
| -91% | -$177K | ﹤0.01% | 3953 |
|
|
2020
Q3 | $199K | Buy |
33
+31
| +1,550% | +$178K | ﹤0.01% | 2582 |
|
|
2020
Q2 | $9K | Buy |
+2
| New | +$10.4K | ﹤0.01% | 4077 |
|
|
2020
Q1 | – | Sell |
-1
| Closed | -$6K | – | 4182 |
|
|
2019
Q4 | $6K | Buy |
+1
| New | +$3.49K | ﹤0.01% | 2641 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | -$3K | – | 4663 |
|
|
2019
Q2 | $3K | Buy |
+1
| New | +$2.79K | ﹤0.01% | 3192 |
|
|
2018
Q2 | – | Sell |
-2
| Closed | -$8K | – | 4212 |
|
|
2018
Q1 | $8K | Buy |
+2
| New | +$13.2K | ﹤0.01% | 2569 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 3393 |
|
|
2017
Q3 | – | Sell |
-3
| Closed | -$22K | – | 4253 |
|
|
2017
Q2 | $22K | Buy |
3
+2
| +200% | +$13.8K | ﹤0.01% | 1173 |
|
|
2017
Q1 | $7K | Hold |
1
| – | – | ﹤0.01% | 2045 |
|
|
2016
Q4 | $8K | Buy |
+1
| New | +$14K | ﹤0.01% | 2800 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3417 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 3580 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | -$12.9K | – | 3850 |
|
|
2015
Q4 | $17K | Buy |
+1
| New | +$15.8K | ﹤0.01% | 1498 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 2707 |
|
|
2015
Q1 | – | Hold |
0
| – | -$2K | – | 5086 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 3422 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 3487 |
|
Other funds holding AGRX
Tower Research Capital (TRC)'s AGRX Position: Q1 2024 in Review
Tower Research Capital (TRC) sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 3,276 shares — an estimated $6.39K sold.
Tower Research Capital (TRC) first reported a position in AGRX in Q4 2015 and held it in 17 quarters. The position peaked at $199K in Q3 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Tower Research Capital (TRC) reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,276 Agile Therapeutics shares in Q1 2024, an estimated $6.39K.
- Tower Research Capital (TRC) first reported a position in Agile Therapeutics in Q4 2015 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Agile Therapeutics position peaked at $199K in Q3 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.